Palvella Loss Widens as Drug Filing Advances
The biotech set full-year cash-expense guidance at $85 million to $95 million.
Palvella Therapeutics (PVLA), a clinical-stage biopharmaceutical company, reported that its second-quarter net loss more than doubled as it advanced its lead rare-disease treatment toward regulatory review.
Palvella completed a pre-NDA meeting with the Food and Drug Administration, secured rolling review and submitted the first module of its application for QTORIN rapamycin in June. The company remained on track to complete the application in the second half of 2026, marking a shift from May, when it was awaiting the meeting.
The net loss widened to $21.9 million, or $1.52 a share, from $9.5 million, or 86 cents a share, a year earlier. Operating expenses rose to $21.4 million from $9.3 million, producing an operating loss of the same amount.
Research-and-development expense climbed 144% to $12.5 million, driven by manufacturing, the angiokeratoma trial, the rolling NDA submission and higher personnel and consulting costs. General and administrative expense increased 116% to $8.9 million as Palvella added employees and absorbed higher public-company professional-services costs.
Cash, cash equivalents and short-term investments declined $11.3 million during the quarter to $250.6 million at June 30, a decrease of about 4.3% from March 31.
Beyond the regulatory submission, Palvella narrowed the planned Phase 3 start for QTORIN rapamycin in cutaneous venous malformations to the fourth quarter from the second half of 2026. The company had also dosed the first patients in its Phase 2 angiokeratoma trial by May, with topline results still expected in the second half of 2027.
Palvella plans to spend $85 million to $95 million in cash during 2026 as it accelerates regulatory, commercial-readiness and pipeline work. The company planned a roughly 40-person U.S. sales force and had engaged more than 200 of an initial 400 target clinics ahead of a potential first-half 2027 launch. Commercial and medical-affairs leaders were already working in the field, while Palvella expanded its patient-access team.
The company also added patent protection through 2043 for QTORIN pitavastatin, its second product candidate, and continues to expect a Phase 2 trial to begin in the second half of 2026.